Daniel C. Gonzalez

Daniel C. Gonzalez

Auto-generated profile, based on publicly available information

Daniel C. Gonzalez

Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2022 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
JOJesse Ory
Jesse Ory
MTMichael B. Tradewell
Michael B. Tradewell
UBUdi Blankstein
Udi Blankstein
TLThiago F. Lima
Thiago F. Lima
SNSirpi Nackeeran
Sirpi Nackeeran
Ranjith RamasamyRanjith Ramasamy
Ranjith Ramasamy
Ory J, et al. World J Mens Health. 2022 Jan;40:e14. https://doi.org/10.5534/wjmh.210159

1 January 2022 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
DGDaniel C. Gonzalez
Daniel C. Gonzalez
JOJesse Ory
Jesse Ory
RBRuben Blachman-Braun
Ruben Blachman-Braun
SNSirpi Nackeeran
Sirpi Nackeeran
JBJordan C. Best
Jordan C. Best
Ranjith RamasamyRanjith Ramasamy
Ranjith Ramasamy
Gonzalez DC, et al. World J Mens Health. 2021 Apr;39:e19. https://doi.org/10.5534/wjmh.200195

1 May 2022 in Urology
Verified
Journal Article
Closed access
DGDaniel C. Gonzalez
Daniel C. Gonzalez
SKShayan Khorsandi
Shayan Khorsandi
MMMegan Mathew
Megan Mathew
EEEkene Enemchukwu
Ekene Enemchukwu
RSRaveen Syan
Raveen Syan

1 September 2020 in Journal of Interferon & Cytokine Research
Verified
Journal Article
Closed access
RPRicardo Pereda
Ricardo Pereda
DGDaniel González
Daniel González
HRHubert Blas Rivero
Hubert Blas Rivero
JRJuan Carlos Rivero
Juan Carlos Rivero
APAlbadio Pérez
Albadio Pérez
RDRodolfo Emilio Domínguez
Rodolfo Emilio Domínguez
A prospective observational study was conducted for assessing the therapeutic efficacy of interferon (IFN)-α2b in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first month after the coronavirus disease 2019 (COVID-19) outbreak began in Cuba. From March 11th to April 14th, 814 patients were confirmed SARS-CoV-2 positive in Cuba. Seven hundred sixty-one (93.4%) were treated with a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular administration of IFN-α2b (Heberon® Alpha R, Center for Genetic Engineering and Biotechnology, Havana, Cuba), 3 times per week, for 2 weeks. Fifty-three patients received the approved COVID protocol without IFN treatment. The proportion of patients discharged from hospital (without clinical and radiological symptoms and nondetectable virus by real-time polymerase chain reaction) was higher in the IFN-treated compared with the non-IFN treated group (95.4% vs. 26.1%, P < 0.01). The case fatality rate (CFR) for all patients was 2.95%, and for those patients who received IFN-α2b the CFR was reduced to 0.92. Intensive care was required for 82 patients (10.1%), 42 (5.5%) had been treated with IFN. This report provides preliminary evidence for the therapeutic effectiveness of IFN-α2b for COVID-19 and suggests that the use of Heberon Alpha R may contribute to complete recovery of patients.

1 January 2021 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
DGDaniel Gonzalez
Daniel Gonzalez
MNManish Narasimman
Manish Narasimman
JBJordan C. Best
Jordan C. Best
JOJesse Ory
Jesse Ory
Ranjith RamasamyRanjith Ramasamy
Ranjith Ramasamy
Gonzalez D, et al. World J Mens Health. 2020 Jan;38:e57. https://doi.org/10.5534/wjmh.200130

1 December 2020 in Research and Reports in Urology
Verified
Journal Article
Open access
PDF file
DGDaniel C Gonzalez
Daniel C Gonzalez
KKKajal Khodamoradi
Kajal Khodamoradi
RPRaghav Pai
Raghav Pai
KGKristopher Guarch
Kristopher Guarch
ZCZachary M Connelly
Zachary M Connelly
Ranjith RamasamyRanjith Ramasamy
Ranjith Ramasamy
Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a virus that is present in most bodily fluids. However, whether SARS-CoV-2 is present in the semen remains underexplored. Thus, we systematically reviewed the existing studies on the presence of SARS-CoV-2 in semen. Methods: A literature search of the PubMed, Embase, Cochrane, Web of Science, Google Scholar, and Ovid databases was performed for articles from the dates of their inception to August 2020 using the following keywords: COVID-19, SARS-CoV2, seminal, semen, and sperm. After excluding non-human studies and articles that were not in the English language, we identified 19 relevant studies. The full text of the articles were reviewed and a total of eight articles remained after applying our selection criteria. Results: After reviewing the presence of SARS-CoV-2 in the eight different studies using semen samples, only one reported the presence of the virus. Six out of 160 total semen samples with SARS-CoV-2 positive demonstrated the presence of viral RNA, of which 2 were from males in the recovery phase and 4 from the acute phase of the infection. Conclusion: The novel nature of SARS-CoV-2 has limited the number and size of studies on semen. Nevertheless, the current literature, while limited, has confirmed the presence of SARS-CoV-2 in semen in one out of the eight reported studies and totaling 4.3% of the population screened. Taken together, the risk of the presence of SARS-CoV-2 in semen appears to be extremely low and likely negligible in recovered men. Future studies need to focus on whether complete viral particles can be seen in semen and the possibility of sexual transmission.